Browsing Tag

Partnering

580 posts

Mylan, Merck & Co, Pfizer, Lilly Outline Relief Efforts for COVID-19
By

By
Mylan donates hydroxychloroquine, a potential COVID-19 treatment. Merck & Co., Pfizer, and Eli Lilly and Company outline relief efforts. Mylan Donates 10 Million Tablets of Potential COVID-19 Drug to US…

Takeda and Evotec Enter Gene-Therapy Research Pact
By

By
Takeda and Evotec GT, an Austria-based subsidiary of Evotec, a Hamburg, Germany-based drug- discovery and development company, have entered into a long-term research alliance to support Takeda’s research-stage gene-therapy discovery…

Gilead, Second Genome Form $338-M Pact for Inflammatory Diseases
By

By
Gilead Sciences and Second Genome, a microbiome clinical-stage company, have entered into a four-year collaboration worth up to $338 million ($38 million upfront and up to $300 million in milestones)…

Pharma Company COVID-19 Roundup: News from Sanofi, AbbVie, and Bayer
By

By
Sanofi forms COVID-19 vaccine research pact and advances clinical testing of antiviral. Bayer and AbbVie contribute to COVID-19 relief efforts. Gates Foundation contributes $1.73 million for antibody research.  Sanofi Advances…

Lilly, Sitryx Form $880-M Licensing and Research Pact
By

By
Eli Lilly and Company and Sitryx, an Oxford, UK-based biopharmaceutical company focused on developing therapeutics in immuno-oncology and immuno-inflammation, have entered a licensing pact in a deal worth up to $880…

Takeda, Evox in $882-M Deal for Rare Diseases
By

By
Takeda has formed a licensing pact with Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, in a deal worth up to $882 million ($44 million upfront) for the development of protein-replacement…

Global Pharma Briefs: News from Asia and the US
By

By
A roundup of developments from India (Bayer, GSK), the US (Boehringer Ingelheim, Lilly, Tetraphase, Amicus), and Japan (Amgen). India Bayer, Curadev Sign Agreement To Develop STING Antagonists Program Bayer and…

J&J Selects COVID-19 Vaccine Candidate; Outlines Plan for Clinical Testing
By

By
Johnson & Johnson (J&J) has selected a lead vaccine candidate against the novel coronavirus (COVID-19) for which it expects to initiate Phase I clinical studies by September 2020 and has…

Daiichi Sankyo, Ultragenyx in Gene-Therapy Mfg Pact Worth Up To $225 M
By

By
Daiichi Sankyo has formed a licensing pact with Ultragenyx Pharmaceutical, a biopharmaceutical company developing drugs for rare and ultra-rare genetic diseases, for the non-exclusive use of Ultragenyx’s adeno associated virus…

Roche, Forge Therapeutics Form Pact for Drug-Resistant Antibiotic
By

By
Roche has formed a research collaboration and option agreement with Forge Therapeutics, a San Diego-based biopharmaceutical company, under for Forge’s FG-LpxC lung, an antibiotic for treating serious lung infections attributed…